HASBROUCK HEIGHTS, N.J., May 14, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009. The increase in net losses is attributable to higher clinical trial expenditures compared to 2009. Product sales increased by 157% to $246,861 for the first quarter of 2010, compared to $96,226 for the same period in 2009. The weighted average number of common shares at March 31, 2010 was 31,473,825, compared to 30,253,246 at March 31, 2009.
